Maternal inhaled nicotine leads to aberrant development of hypertensive phenotype

Information

  • Research Project
  • 10064004
  • ApplicationId
    10064004
  • Core Project Number
    R01HL135623
  • Full Project Number
    5R01HL135623-05
  • Serial Number
    135623
  • FOA Number
    RFA-HL-17-008
  • Sub Project Id
  • Project Start Date
    1/1/2017 - 8 years ago
  • Project End Date
    11/30/2021 - 3 years ago
  • Program Officer Name
    COOPER, LAWTON S
  • Budget Start Date
    12/1/2020 - 4 years ago
  • Budget End Date
    11/30/2021 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    05
  • Suffix
  • Award Notice Date
    11/20/2020 - 4 years ago
Organizations

Maternal inhaled nicotine leads to aberrant development of hypertensive phenotype

Inhaled nicotine abuse either from tobacco cigarette or e-cigarette smoking is one of the most important risk factors in development of cardiovascular disease. Recent studies in women and animal models indicate that cigarette smoking or nicotine use by mothers during pregnancy increases the risk of hypertension and cardiovascular diseases in offspring. Oxidative stress has been implicated in the etiology of many diseases with substantial public health impact including chronic cardiovascular disorders and preeclampsia. Our recent studies in pregnant rats have demonstrated that perinatal nicotine exposure causes a development of vascular dysfunctional phenotype associated with an increased vascular specific NADPH oxidase (NOX2) gene expression and reactive oxygen species (ROS) production in adult offspring. However, the molecular mechanisms underlying nicotine-mediated programming of vascular oxidative stress are unclear. In addition, whether the heightened oxidative stress contributes to development of hypertensive phenotype remains undetermined. Recently, our research team has developed a non-invasive method delivering nicotine to rodents through inhalation with lung alveolar region-targeted aerosol technology (patent No. 61/418,304) that enables rapid delivery of adequate and controllable amount of nicotine into the circulation. This method closely resembles the route and both the arterial and venous blood nicotine kinetics of smoking a cigarette in human, and induces dose-dependent pharmacological effects in rodents. Our previous data show that chronic intermittent nicotine aerosol treatment (CINA) to rats produces circadian blood pharmacokinetics resembling chronic smokers. Therefore, in this proposed studies we will use the unique CINA pregnant rat model to test the central hypothesis that antenatal exposure to maternal inhaled nicotine programs vascular oxidative stress via epigenetic up-regulation of NOX2 gene, resulting in a hypertensive phenotype in offspring. Our working Specific Aim 1 will determine nicotine pharmacokinetics (PK) in CINA inhaled pregnant rats with our novel alveolar region-targeted aerosol technology and adjust the parameters of aerosol generation/exposure to simulate the PK of human chronic smokers. Specific Aim 2 will test the hypothesis that antenatal inhaled nicotine programs of vascular oxidative stress via epigenetic up-regulation of NOX2 expression. Specific Aim 3 will test the hypothesis that antenatal inhaled nicotine causes a development of hypertensive phenotype which is regulated by NOX2-related ROS signaling. The proposed studies will resolve whether maternal inhaled nicotine during pregnancy programs fetal oxidative stress and contributes to the development of hypertensive phenotype in adulthood. Innovative approaches in these studies provide the opportunity to identify epigenetic biomarkers during early life that have diagnostic and preventive value to the consequences of in utero adverse environmental exposure-induced cardiovascular disease in adulthood.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    291196
  • Indirect Cost Amount
    96256
  • Total Cost
    387452
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:387452\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZHL1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LOMA LINDA UNIVERSITY
  • Organization Department
    INTERNAL MEDICINE/MEDICINE
  • Organization DUNS
    009656273
  • Organization City
    LOMA LINDA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    923500225
  • Organization District
    UNITED STATES